Avidity biosciences announces changes to its board of directors

La jolla, calif., aug. 25, 2021 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna) a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the appointment of experienced global commercial and operations executive, eric mosbrooker to its board of directors.
RNA Ratings Summary
RNA Quant Ranking